Aquinox Pharmaceuticals Debt to Equity Ratio 2013-2018 | AQXP

Current and historical debt to equity ratio values for Aquinox Pharmaceuticals (AQXP) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Aquinox Pharmaceuticals debt/equity for the three months ending December 31, 2018 was 0.00.
Aquinox Pharmaceuticals Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-12-31 $0.00B $0.07B 0.00
2018-09-30 $0.00B $0.08B 0.00
2018-06-30 $0.00B $0.09B 0.00
2018-03-31 $0.00B $0.09B 0.00
2017-12-31 $0.00B $0.10B 0.00
2017-09-30 $0.00B $0.11B 0.00
2017-06-30 $0.00B $0.13B 0.00
2017-03-31 $0.00B $0.14B 0.00
2016-12-31 $0.00B $0.15B 0.00
2016-09-30 $0.00B $0.16B 0.00
2016-06-30 $0.00B $0.09B 0.00
2016-03-31 $0.00B $0.10B 0.00
2015-12-31 $0.00B $0.11B 0.00
2015-09-30 $0.00B $0.11B 0.00
2015-06-30 $0.00B $0.03B 0.00
2015-03-31 $0.00B $0.03B 0.00
2014-12-31 $0.00B $0.04B 0.00
2014-09-30 $0.00B $0.04B 0.00
2014-06-30 $0.00B $0.05B 0.00
2014-03-31 $0.00B $0.06B 0.00
2013-12-31 $0.00B $-0.07B -0.03
2013-09-30 $0.00B $0.00B 0.00
2013-06-30 $0.00B $0.00B 0.00
2013-03-31 $0.00B $0.00B 0.00
2012-12-31 $0.00B $-0.05B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.064B $0.025B
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $49.659B 8.94
Teva Pharmaceutical Industries (TEVA) Israel $16.606B 5.73
Mylan (MYL) United Kingdom $14.803B 6.26
Bausch Health Cos (BHC) Canada $8.636B 6.14
Dr Reddy's Laboratories (RDY) India $6.502B 25.93
Supernus Pharmaceuticals (SUPN) United States $1.866B 17.31
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.845B 3.00
Homology Medicines (FIXX) United States $0.967B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.943B 87.65
CymaBay Therapeutics (CBAY) United States $0.709B 0.00
Voyager Therapeutics (VYGR) United States $0.586B 0.00
Assembly Biosciences (ASMB) United States $0.465B 0.00
Akorn (AKRX) United States $0.440B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.366B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.210B 0.00
Sol-Gel Technologies (SLGL) Israel $0.127B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.122B 0.00
Acasti Pharma (ACST) Canada $0.082B 0.00
Agile Therapeutics (AGRX) United States $0.064B 0.00
Teligent (TLGT) United States $0.062B 0.00
Evoke Pharma (EVOK) United States $0.025B 0.00
Aevi Genomic Medicine (GNMX) United States $0.014B 0.00